Danuta M. Skowronski
YOU?
Author Swipe
View article: Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada
Measles seroprevalence by birth cohort across the lifespan: a population-based, cross-sectional serosurvey in British Columbia, Canada Open
Our measles serosurvey findings inform vaccine coverage and complement other case-based surveillance indicating robust population-level immunity outside of unvaccinated clusters or communities. In addition to showing age-related antibody d…
View article: Effectiveness of 2024/25 KP.2 vaccine against outpatient COVID-19 in Canada
Effectiveness of 2024/25 KP.2 vaccine against outpatient COVID-19 in Canada Open
Between November 2024 and April 2025, the Canadian Sentinel Practitioner Surveillance Network assessed KP.2 vaccine effectiveness against outpatient COVID-19 by test-negative design. Vaccination protected best during the first two months, …
View article: Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada
Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes in preterm, high-risk and healthy-term infants, Quebec, Canada Open
Background During the 2024-25 season, a universal infant nirsevimab program was publicly funded in Quebec, Canada. We estimated effectiveness, number-needed-to-immunize (NNI) and impact against severe respiratory syncytial virus (RSV) outc…
View article: RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions
RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions Open
Importance National Immunization Technical Advisory Groups recommend long-acting monoclonal antibody prophylaxis for the prevention of respiratory syncytial virus (RSV) disease for children at high risk in the first season, regardless of R…
View article: Neuraminidase imprinting and the age-related risk of zoonotic influenza
Neuraminidase imprinting and the age-related risk of zoonotic influenza Open
Highly pathogenic avian influenza of the H5N1 subtype has shown recent unprecedented expansion in its geographic and host range, increasing the pandemic threat. The younger age of H5N1 versus H7N9 avian influenza in humans has previously b…
View article: Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-Omicron and Omicron periods
Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-Omicron and Omicron periods Open
Background We estimated vaccine effectiveness (VE) against COVID-19 and long COVID during pre-Omicron and Omicron periods, by number of doses and prior infection history. Methods We combined survey information from a cohort of healthcare w…
View article: Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies, in British Columbia, Canada
Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies, in British Columbia, Canada Open
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in young children and results in significant healthcare burden and costs. To reduce the impact of RSV in this population, the monoclonal …
View article: Antiviral therapy for HPAI and reported oseltamivir resistance in Canada
Antiviral therapy for HPAI and reported oseltamivir resistance in Canada Open
View article: Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: Impact of variant replacement and waning protection during 10-month follow-up Open
Background Vaccine formulations targeting contemporaneous subvariants have been developed to respond to SARS-CoV-2 virus evolution. Updated monovalent COVID-19 vaccines targeting the Omicron XBB.1.5 variant (XBB-vaccines) were administered…
View article: Long COVID risk and severity after COVID-19 infections and reinfections in Quebec healthcare workers
Long COVID risk and severity after COVID-19 infections and reinfections in Quebec healthcare workers Open
Importance Long COVID, a chronic condition following SARS-CoV-2 infection, affects millions of people worldwide and can lead to significant functional impairment. Estimates of long COVID risk after a first COVID-19 infection vary, and data…
View article: Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25
Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25 Open
The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 a…
View article: Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up
Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up Open
Background. We evaluated mRNA COVID–19 vaccine effectiveness (VE) for the XBB.1.5 formulation against COVID–19 hospitalizations among adults aged ≥60 years during a ten–month follow–up period. Methods. We conducted a test–negative case–con…
View article: Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada
Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada Open
Clinicaltrials.gov, NCT0470294.
View article: Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study
Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study Open
To evaluate immune responses to COVID-19 vaccines in adults aged 50 years and older, spike protein (S)-specific antibody concentration, avidity, and function (via angiotensin-converting enzyme 2 (ACE2) inhibition surrogate neutralization a…
View article: 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN) Open
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (6…
View article: Children with Chronic Medical Conditions at Risk for Severe Rsv Infection in Their First Two Seasons
Children with Chronic Medical Conditions at Risk for Severe Rsv Infection in Their First Two Seasons Open
View article: 1158. Immunogenicity of COVID-19 vaccine four-dose series in healthy community dwelling adults 50 years and above: interim analysis from the ‘PRospEctiVe EvaluatioN of immuniTy after COVID-19 vaccines’ (PREVENT-COVID) study
1158. Immunogenicity of COVID-19 vaccine four-dose series in healthy community dwelling adults 50 years and above: interim analysis from the ‘PRospEctiVe EvaluatioN of immuniTy after COVID-19 vaccines’ (PREVENT-COVID) study Open
Background Adults aged > 50 years are at increased risk for severe coronavirus disease 2019 (COVID-19). This study evaluated immunogenicity of COVID-19 vaccines in healthy adults aged > 50 years through quantification of antigen spec…
View article: 1165. Longitudinal Evaluation of SARS-CoV-2 Antibody Response Using Dried Blood Spot Samples Following Vaccination with Three and Four Doses of mRNA-1273, BNT162b2 and/or ChAdOx1-S in Adults Aged 50 and Above: Interim Analysis from the PREVENT-COVID Study
1165. Longitudinal Evaluation of SARS-CoV-2 Antibody Response Using Dried Blood Spot Samples Following Vaccination with Three and Four Doses of mRNA-1273, BNT162b2 and/or ChAdOx1-S in Adults Aged 50 and Above: Interim Analysis from the PREVENT-COVID Study Open
Background Multiple combinations of COVID-19 vaccine regimens have been used in Canada throughout the SARS-CoV-2 immunization campaign. Studies evaluating the humoral immune response following COVID-19 vaccination in community dwelling old…
View article: Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status
Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status Open
Background Annual influenza vaccination is recommended for older adults but repeated vaccination with standard-dose influenza vaccine has been linked to reduced immunogenicity and effectiveness, especially against A(H3N2) viruses. Methods …
View article: Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada
Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada Open
By July 2023, we estimated about 80% of residents in the Lower Mainland, BC, had been infected with SARS-CoV-2 overall, with low risk of hospital admission or death; about 40% of the oldest adults, however, remained uninfected and at highe…
View article: Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk
Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk Open
Introduction During the 2022 mpox outbreak, the province of Quebec, Canada, prioritized first doses for pre-exposure vaccination of people at high mpox risk, delaying second doses due to limited supply. We estimated single-dose mpox vaccin…
View article: Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2
Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2 Open
View article: Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study
Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study Open
View article: Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults > 50 years: a prospective, observational cohort study
Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults > 50 years: a prospective, observational cohort study Open
To evaluate immune responses to COVID-19 vaccines in adults aged 50 years and older, spike protein (S)-specific antibody concentration, avidity, and function (angiotensin-converting enzyme 2 (ACE2) inhibition surrogate neutralization, anti…
View article: Influenza hospitalization burden by subtype, age, comorbidity and vaccination status: 2012/13 to 2018/19 seasons, Quebec, Canada
Influenza hospitalization burden by subtype, age, comorbidity and vaccination status: 2012/13 to 2018/19 seasons, Quebec, Canada Open
Background The primary objective of influenza immunization programs is to reduce the risk and burden of severe outcomes. To inform optimal program strategies, we monitored influenza hospitalizations over several seasons of varying subtype …
View article: Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada Open
For the French translation of the abstract see Supplementary Materials section.
View article: Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk
Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk Open
Introduction During the 2022 mpox outbreak, the province of Quebec, Canada prioritized first doses for pre-exposure vaccination of people at high mpox risk, delaying second doses due to limited supply. We estimated single-dose mpox vaccine…
View article: Signatures of Original Antigenic Sin or protection following coronavirus imprinting in Syrian hamsters challenged with SARS-CoV-2 or variants
Signatures of Original Antigenic Sin or protection following coronavirus imprinting in Syrian hamsters challenged with SARS-CoV-2 or variants Open
Coronaviruses are a significant threat to public health, animal welfare, and economic stability. SARS-CoV-2 and seasonal coronaviruses continue to cause disease and coronaviruses in the animal reservoir pose a constant spillover threat. Im…
View article: Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23 Open
The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversi…
View article: BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration Open
Background Two- and 3-dose BNT162b2 vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including Delta and Omicron variants, was assessed among adolescents in Canada, where first and …